Clinical Trials in Michigan

Showing 5901-5920 of 16,154 trials

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

NCT04723537

A 2-part, multicenter, Phase 2/3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of upamostat in adult patients with COVID-19 disease who do not require inpatient care.

Covid19

RedHill Biopharma Limited61 participantsStarted Feb 2021

Cutler Bay, Florida, United States • Hialeah, Florida, United States • Miami, Florida, United States +14 more locations

UNKNOWNPhase 162 miles

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

NCT06270706

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from the start of treatment with pembrolizumab. The study will consist of 2 main parts: * Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design * Part 2: Dose-expansion cohorts using Simon's 2-stage design

Metastatic Solid Tumor

Pliant Therapeutics, Inc.77 participantsStarted Aug 2023

New Haven, Connecticut, United States • Grand Rapids, Michigan, United States • Austin, Texas, United States +2 more locations

Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Find Trials by Condition in Michigan

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Prospective Evaluation of the LithoVue Elite Ureteroscope

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Trial for Treatment Refractory Trigeminal Neuralgia

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS